Spark Therapeutics (ONCE) Tops Q1 EPS by 2c

Spark Therapeutics (NASDAQ: ONCE) reported Q1 EPS of ($0.56), $0.02 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.2 million.

As of March 31, 2015, Spark had cash and cash equivalents of $234.4 million, with 24.5 million shares outstanding.

"We have had a productive and exciting start to 2015. In February, we successfully completed our initial public offering while making meaningful advancements in all of our product development programs and building our organization," said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. "Further, on the technology in-licensing front, as we announced last week, we are excited about the possibilities that Clearside Biomedical's microinjector technology may bring to the development of potentially differentiated gene therapies for inherited retinal degenerations (IRDs)."

For earnings history and earnings-related data on Spark Therapeutics (ONCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49